样式: 排序: IF: - GO 导出 标记为已读
-
Proof of concept of physiologically based pharmacokinetic modelling in paediatric acute lymphoblastic leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-17 Thomas Bauch, Georg Hempel
Physiologically based pharmacokinetic (PBPK) modelling is an alternative modelling technique that is increasingly used in pharmacokinetics. Due to its nature, it can be complementarily employed to population pharmacokinetics, especially when it comes to small population size. Here, we report the proof of concept of its application to accurately describe the pharmacokinetics of a recombinant L-asparaginase
-
Challenging the dogma: Red blood cell-directed autoimmunity as risk factor for red blood cell alloimmunisation after blood transfusion Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-17 Josine A. Oud, Masja de Haas, Karen M. K. de Vooght, Daan van de Kerkhof, Nel Som, Nathalie C. V. Péquériaux, Francisca Hudig, Johanna G. van der Bom, Dorothea Evers, Jaap Jan Zwaginga
Red blood cell autoimmunity and alloimmunity are potentially linked. Quantification of this association can tailor extensively matched red blood cell transfusions in patients with autoimmunity. Using an incident new-user cohort comprising 47 285 previously non-transfused, non-alloimmunised patients, we compared transfusion-induced red blood cell alloimmunisation incidences in direct antiglobulin test
-
Practice guideline: Preparation for CAR T‐cell therapy in children and young adults with B‐acute lymphoblastic leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-16 Avijeet Kumar Mishra, Saskia Burridge, Macarena Oporto Espuelas, Maeve O'Reilly, Michelle Cummins, Emma Nicholson, Sophie Wheldon, Denise Bonney, Geoff Shenton, David I. Marks, Persis J. Amrolia, Rachael Hough, Sara Ghorashian
SummaryThe objective of this guideline, prepared by the ALL subgroup of the Advanced Cell Therapy Sub‐Committee of BSBMTCT (British Society of Blood and Marrow Transplantation), is to provide healthcare professionals with practical guidance on the preparation of children and young adults with B‐acute lymphoblastic leukaemia from the point of referral to that of admission for CAR T‐cell treatment. The
-
Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-14 Kate Manos, Leonid Churilov, Andrew Grigg, Pietro Di Ciaccio, Jonathan Wong, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K. Yannakou, Nada Hamad, Gareth P. Gregory, Shane Gangatharan, Tara Cochrane, Eliza A. Hawkes, Masa Lasica
-
Understanding complex disease-related mechanisms: Rational therapies for Diamond–Blackfan anaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-14 Jeffrey M. Lipton
The rich history surrounding Diamond–Blackfan anaemia (DBA), originally described in 1938 as congenital hypoplastic anaemia2 reflects the evolution of paediatric haematology. In their paper, the authors1 present the results of a clinical trial using the thrombopoietin-mimetic agent eltrombopag to treat red cell failure in DBA. A low response rate belies the importance of this work.
-
Refining risk stratification in paediatric B-acute lymphoblastic leukaemia: Combining IKZF1plus and Day 15 MRD positivity Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-13 Hsi-Che Liu, Ying-Jung Huang, Tang-Her Jaing, Kang-Hsi Wu, Shih-Hsiang Chen, Shih-Chung Wang, Ting-Chi Yeh, Chih-Cheng Hsiao, Te-Kau Chang, Hsiu-Ju Yen, Fang-Liang Huang, Pei-Chin Lin, Jen-Yin Hou, Jiunn-Ming Sheen, Yu-Mei Liao, Tsung-Yen Chang, Yu-Chieh Chen, Shyh-Shin Chiou, Chao-Ping Yang, Ching-Hon Pui, Der-Cherng Liang, Lee-Yung Shih
-
Successful treatment of scleromyxoedema with daratumumab Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-12 Katharina Epp, Raphael Teipel, Ulrike Reuner, Martin Bornhäuser, Claudia Günther, Karolin Trautmann-Grill
Scleromyxoedema is a rare mucinous disease associated with monoclonal gammopathy. Treatment can be difficult, especially in severe cases with extracutaneous involvement such as dermato-neuro syndrome.1 A 51-year-old female patient with scleromyxoedema was referred to our haematology department in 2008. She had first been diagnosed in 1992 and was known to have accompanying monoclonal gammopathy of
-
DNA methylation profiling of myelodysplastic syndromes and clinical response to azacitidine: A multicentre retrospective study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-12 Aleix Noguera-Castells, Ignacio Campillo-Marcos, Veronica Davalos, Carlos A. García-Prieto, David Valcárcel, Antonieta Molero, Laura Palomo, Norbert Gattermann, Michael Wulfert, Lorea Chaparro-González, Francesc Solé, Marta Cabezón, María J. Jiménez-Lorenzo, Blanca Xicoy, Lurdes Zamora, Alessia De Stefano, Irene Casalin, Carlo Finelli, Matilde Y. Follo, Manel Esteller
Real-world data have revealed that a substantial portion of patients with myelodysplastic syndromes (MDS) does not respond to epigenetic therapy with hypomethylating agents (HMAs). The cellular and molecular reasons for this resistance to the demethylating agent and biomarkers that would be able to predict the treatment refractoriness are largely unknown. In this study, we shed light on this enigma
-
Left ventricular global longitudinal strain and acute myocardial injury in patients with sickle cell disease admitted to the intensive care unit for vaso-occlusive crisis Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-12 Guillaume Roger, Pierre Denormandie, Thibaut Gobe, Danila Azzolina, Tài Pham, Christelle Chantalat, Daphnée Cuveillier, Amir Bouchachi, Patrick Jourdain, Christopher Lai, Arthur Pavot, Nicolas Fage, Paul Domnariu, Jean-Louis Teboul, Xavier Monnet
-
-
Waldenstrom macroglobulinaemia with AA amyloidosis reveals a B‐cell‐restricted NLRP2 variant Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-11 Alexandre Terré, David Buob, Alexandre Cez, Mathieu P. Rodero, Sophie Georgin‐Lavialle
-
Capture‐based targeted sequencing using a T‐cell control in myeloid malignancies and idiopathic cytopenias Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-11 Grzegorz Pietka, Corinne De Lord, Gwynn Matthias, Betty Cheung, Sangeeta Atwal, Michelle Furtado, Jonathan Cullis, Liz Grey‐Davies, Srinivasan Narayanan, Andrew McGregor, Mari Kilner, Jenny Bosworth, Mary Frances McMullin, Thomas Coats, Agapi Parcharidou, Jamie Cavenagh, Jenny Byrne, Sunil Iyengar, Kabir Mohammed, Nicholas Cross, Mike Hubank, Sara Ribeiro, Jamshid Khorashad, Dorte Wren, Simon O'Connor
SummaryWe report on a study of next‐generation sequencing in 257 patients undergoing investigations for cytopenias. We sequenced bone marrow aspirates using a target enrichment panel comprising 82 genes and used T cells from paired blood as a control. One hundred and sixty patients had idiopathic cytopenias, 81 had myeloid malignancies and 16 had lymphoid malignancies or other diagnoses. Forty‐seven
-
Identification of COQ2 as a regulator of proliferation and lipid peroxidation through genome‐scale CRISPR‐Cas9 screening in myeloma cells Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-11 Miao Li, Chang‐lin Zhang, Di‐sheng Zhou, Sze‐Hoi Chan, Xue‐Qi Liu, Shu‐Na Chen, Zi‐Yi Yang, Fei‐er Ju, Xiao‐yan Sang, Zi‐xuan Liu, Qiao‐Xia Zhang, Yu‐ming Pan, Si‐si Deng, Xiao‐Mei Wang, Li Zhong, Xing‐Ding Zhang, Xin Du
SummaryMultiple myeloma (MM) is the second most common malignant haematological disease with a poor prognosis. The limit therapeutic progress has been made in MM patients with cancer relapse, necessitating deeper research into the molecular mechanisms underlying its occurrence and development. A genome‐wide CRISPR‐Cas9 loss‐of‐function screening was utilized to identify potential therapeutic targets
-
Treatment of refractory/relapsed Diamond–Blackfan anaemia with eltrombopag Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-11 Brynn B. Duncan, Jennifer L. Lotter, Jeanine Superata, Ma Evette Barranta, Tania Machado, Ivana Darden, Sanjay Venugopal, Colin O. Wu, Janis L. Abkowitz, Cynthia E. Dunbar, David J. Young
-
CXCR4 WHIM syndrome is a cancer predisposition condition for virus-induced malignancies Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-05 Clémentine Moulin, Blandine Beaupain, Felipe Suarez, Yves Bertrand, Sarah Cohen Beaussant, Alain Fischer, Julie Durin, Dana Ranta, Marion Espéli, Françoise Bachelerie, Christine Bellanné-Chantelot, Thierry Molina, Jean François Emile, Karl Balabanian, Claire Deback, Jean Donadieu
-
Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-05 Roberta Sciarra, Michele Merli, Caterina Cristinelli, Marco Lucioni, Silvia Zibellini, Roberta Riboni, Daniela Furlan, Silvia Uccella, Caterina Zerbi, Benedetta Bianchi, Manuel Gotti, Virginia Valeria Ferretti, Chiara Varraso, Sara Fraticelli, Tanja Lazic, Irene Defrancesco, Barbara Mora, Laura Libera, Alessandro Mazzacane, Federico Carpi, Martha Berliner, Giuseppe Neri, Ettore Rizzo, Federica De Paoli
-
Increased donor inhibitory KIR are associated with reduced GVHD and improved survival following HLA-matched unrelated donor HCT in paediatric acute leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-05 Elizabeth Krieger, Rehan Qayyum, Amir Toor
-
Metabolomics profile and machine learning prediction of treatment responses in immune thrombocytopenia: A prospective cohort study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-04 Yang Li, Ting Sun, Jia Chen, Xiaofan Liu, Rongfeng Fu, Feng Xue, Wei Liu, Mankai Ju, Xinyue Dai, Huiyuan Li, Wentian Wang, Ying Chi, Ting Li, Shuai Shao, Renchi Yang, Yunfei Chen, Lei Zhang
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by antibody-mediated platelet destruction and impaired platelet production. The mechanisms underlying ITP and biomarkers predicting the response of drug treatments are elusive. We performed a metabolomic profiling of bone marrow biopsy samples collected from ITP patients admission in a prospective study of the National Longitudinal
-
Longitudinal evaluation of adverse events due to steroid use in primary immune thrombocytopenia: A population-based study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-04 Jiaan-Der Wang, Fan-Chen Ku, I-Ju Chiang, Meng-Yun Ku, Yi-Ming Chen, Li-Nien Chien
-
Epidemiological features and prognosis for primary gastrointestinal follicular lymphoma Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-06 Xuelei Li, Fenghua Gao, Xiangrui Meng, Xiaoyan Zhang, Cong Sun, Hengqi Liu, Jingwei Yu, Xia Liu, Xue Han, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Wenchen Gong, Zahra Golchehre, Zahra Chavoshzadeh, Xiubao Ren, Xianhuo Wang, Huilai Zhang
-
Correctly marking the 70th anniversary of Castleman disease Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-06 Sanya Sukpanichnant
-
Correctly marking the 70th anniversary of Castleman disease—Response Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-06 Arianna Di Napoli, Sabrina Pelliccia, Evelina Rogges
-
Relevance of CD20 antigen expression among paediatric patients with B‐lineage acute lymphoblastic leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-06 Karthik Bommannan, Jhansi Rani Arumugam, Venkatraman Radhakrishnan, Shirley Sundersingh
SummaryLiterature regarding prognostic relevance of CD20 antigen expression among paediatric B‐lineage acute lymphoblastic leukaemia (B‐ALL) patients is sparse and contradictory. We analysed clinical laboratory parameters and survival characteristics pertinent to CD20 expression among 224 treatment‐naïve paediatric B‐ALL patients. 50% patients had CD20 expression (CD20+ B‐ALL). There was no difference
-
Prolonged coagulation times in severe fever with thrombocytopenia syndrome virus infection, the indicators of heparin‐like effect and increased haemorrhagic risk Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-05 Ning Tang, Peihong Yuan, Ming Luo, Dengju Li
-
High‐dose methotrexate pharmacokinetics and its impact on prognosis of paediatric acute lymphoblastic leukaemia patients: A population pharmacokinetic study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-03 Xiaoxiao Chen, Jing Li, Liting Yu, Wenting Hu, Jiaoyang Cai, Zhuo Wang, Changcheng Chen, Xin Zhang, Yangyang Xie, Kefei Wu, Yixiao Mo, Jihui Chen, Shuhong Shen
-
Autoimmune cytopenia and Kabuki syndrome in paediatrics: Insights in 11 patients Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-03 Chloé Bianchi, Henri Margot, Helder Fernandes, Marlène Pasquet, Laurence Priqueler, Frédérique Roy‐Peaud, Frédéric Bauduer, Sophie Bayart, Nathalie Garnier, Olivier Fain, Julien Van Gils, Sandrine Baron Joly, Fanny Rialland, Catherine Paillard, Marianna Deparis, Anne Lambilliotte, Thierry Leblanc, Mony Fahd, Guy Leverger, Sébastien Héritier, David Geneviève, Frédéric Rieux‐Laucat, Capucine Picard,
-
Faster clinical decisions in B‐cell acute lymphoblastic leukaemia: A single flow cytometric 12‐colour tube improves diagnosis and minimal residual disease follow‐up Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-03 Benjamin Lebecque, Joevin Besombes, Louis‐Thomas Dannus, Marie De Antonio, Victoria Cacheux, Victoria Grèze, Valentin Montagnon, Lauren Veronese, Andrei Tchirkov, Olivier Tournilhac, Marc G. Berger, Richard Veyrat‐Masson
-
Smouldering multiple myeloma: To seek or not to seek? To treat or not to treat. That is the question Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-02 Iuliana Vaxman, Moshe E. Gatt
In this issue, the British Society for Haematology presents guidelines for the diagnosis and management of patients with smouldering multiple myeloma (SMM). The authors provide a practical, evidence‐based approach to managing these patients. Key questions remain yet unsolved.Commentary on: Hughes et al. Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice
-
Real‐world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: Results from the TRAIT study Br. J. Haematol. (IF 6.5) Pub Date : 2024-03-02 Nichola Cooper, Marie Scully, Charles Percy, Phillip L. R. Nicolson, Gillian Lowe, Catherine N. Bagot, Jecko Thachil, Henri Grech, Tim Nokes, Quentin A. Hill, Charlotte Bradbury, Kate Talks, Tina Dutt, Gillian Evans, Sue Pavord, Sarah Wexler, Asad Charania, Sarah J. Collington, Andrew Ervin, Nicholas Ramscar, Drew Provan
SummaryFew studies have reported the real‐world use of both romiplostim and eltrombopag in immune thrombocytopenia (ITP). TRAIT was a retrospective observational study aimed to evaluate the platelet responses and adverse effects associated with the use of these thrombopoietin receptor agonists (TPO‐RAs) in adult patients with ITP in the United Kingdom. Of 267 patients (median age at diagnosis, 48 years)
-
First complete remission favours haploidentical haematopoietic stem cell transplantation with post-transplant cyclophosphamide over cord blood transplantation in acute lymphoblastic leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-29 Tomoyasu Jo, Tomoaki Ueda, Yu Akahoshi, Tadakazu Kondo, Naoyuki Uchida, Masatsugu Tanaka, Hirohisa Nakamae, Noriko Doki, Shuichi Ota, Masashi Sawa, Hiroyuki Ohigashi, Yumiko Maruyama, Nobuyuki Takayama, Tetsuya Nishida, Nobuhiro Hiramoto, Yuta Katayama, Yoshinobu Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Yasuyuki Arai
To assess the benefits of HLA-haploidentical haematopoietic stem cell transplantation using post-transplant cyclophosphamide (PTCy-haplo) relative to those of umbilical cord blood (UCB) transplantation in acute lymphoblastic leukaemia (ALL), we analysed 1999 patients (PTCy-haplo, 330; UCB, 1669), using the nationwide Japanese registry. PTCy-haplo was associated with a significantly higher relapse rate
-
Mitigating the impact of blood shortages in England Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-29 Fateha Chowdhury, Lise Estcourt, Michael F. Murphy
SummaryThe supply of blood components and products in sufficient quantities is key to any effective health care system. This report describes the challenges faced by the English blood service, NHS Blood and Transplant (NHSBT), towards the end of the COVID‐19 pandemic, which in October 2022 led to an Amber Alert being declared to hospitals indicating an impending blood shortage. The impact on the hospital
-
ABO non‐identical platelet transfusions, immune platelet refractoriness and platelet support Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-29 Min‐Hi Han, Krishna Govind Badami
-
Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3 Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-29 Mohamad Mohty, Nizar J. Bahlis, Ajay K. Nooka, Marco DiBonaventura, Jinma Ren, Umberto Conte
SummaryThe physical and emotional burden of relapsed or refractory multiple myeloma (RRMM) has been strongly correlated with declining health‐related quality of life (QOL) in the patients it affects. This analysis evaluated patient‐reported outcomes (PROs) from B‐cell maturation antigen (BCMA)‐naive (n = 123) and ‐exposed (n = 64) patients with RRMM enrolled in the MagnetisMM‐3 study (NCT04649359)
-
Ethnicity and socio‐economic status affects the incidence and survival of hepatosplenic T‐cell lymphoma Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-29 Mark J. Bishton, Colin J. Crooks, Timothy R. Card, Joe West
SummaryTo address the lack of contemporary population‐based epidemiological studies of hepatosplenic T‐cell lymphoma (HSTCL), we undertook a population‐based study of ICD‐O‐3‐coded HSTCL in England. We used the National Cancer Registration Dataset and linked datasets on hospital admissions, Systemic Anti‐Cancer Therapy, socio‐demographics, comorbidities and death, identifying cases from 1 January 2013
-
Small RNA‐seq and clinical evaluation of tRNA‐derived fragments in multiple myeloma: Loss of mitochondrial i‐tRFHisGTG results in patients' poor treatment outcome Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-28 Konstantinos Soureas, Maria‐Alexandra Papadimitriou, Panagiotis Malandrakis, Aristea‐Maria Papanota, Panagiotis G. Adamopoulos, Ioannis Ntanasis‐Stathopoulos, Christine‐Ivy Liacos, Maria Gavriatopoulou, Diamantis C. Sideris, Efstathios Kastritis, Meletios‐Athanasios Dimopoulos, Andreas Scorilas, Evangelos Terpos, Margaritis Avgeris
-
Biallelic hexokinase 1 (HK1) variants causative of non‐spherocytic haemolytic anaemia: A case series with emphasis on the HK1 promoter variant and literature review Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-28 Elli‐Maija Ukonmaanaho, Silvia Dell'Anna, Anna Hakonen, Ulla Wartiovaara‐Kautto, Sakari Kakko, Minke A. E. Rab, Brigitte van Oirschot, Minna Kraatari‐Tiri, Richard van Wijk, Elisa Rahikkala
-
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-27 Nathacha Jimkap, Oussama El Baroudi, Jean Lemoine, Daniele Pievani, Cédric Pastoret, Roch Houot
-
Validation of the Artificial Intelligence Prognostic Scoring System for Myelodysplastic Syndromes in chronic myelomonocytic leukaemia: A novel approach for improved risk stratification Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-27 Adrian Mosquera Orgueira, Manuel Mateo Perez Encinas, Nicolas Diaz Varela, Yu‐Hung Wang, Elvira Mora, Marina Diaz‐Beya, Maria Julia Montoro, Helena Pomares Marin, Fernando Ramos Ortega, Mar Tormo, Andres Jerez, Josep Nomdedeu, Carlos de Miguel Sanchez, Leonor Arenillas, Paula Carcel, Maria Teresa Cedena Romero, Blanca Xicoy Cirici, Eugenia Rivero Arango, Rafael Andrés Del Orbe Barreto, Luis Benlloch
-
Correlation of T‐cell receptor constant beta‐chain 1 by flow cytometry with molecular T‐cell receptor clonality for the investigation of T‐cell lymphoproliferation Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-26 Tania Dexter, Tosin Taiwo, Claire Dearden, Li Yuan Chan, David Taussig, Dima El‐Sharkawi, Alan Dunlop, Sunil Iyengar
-
Etoposide combined with cytarabine and pegfilgrastim for poorly mobilizing patients with multiple myeloma and lymphoma: A prospective multicentre study Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-24 Peipei Ye, Yixuan Cheng, Jiaying Lian, Hongyan Tong, Linjie Li, Qunyi Guo, Weiguo Zhu, Weiying Feng, Li Huang, Lihong Shou, Dong Chen, Xuhui Liu, Shuangyue Li, Xiaohong Du, Min Yang, Wenjuan Yu, Jiejing Qian, Chao Hu, Huafeng Wang, Yangjin Jin, Jian Shen, Pan Hong, Renzhi Pei, Jie Jin, Ying Lu
SummaryA chemotherapy‐based mobilization regimen in patients who mobilize poorly, based on etoposide, cytarabine and pegfilgrastim (EAP), has recently been introduced. The aim of this prospective study was to investigate the efficacy and safety of the EAP regimen in patients with poorly mobilizing multiple myeloma (MM) or lymphoma. This single‐arm clinical trial was performed at eight public hospitals
-
Outcome of malignant lymphoma in Ukraine. Analysis of 563 cases registered in the Ukrainian Lymphoma Registry in 2019–2021 Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-24 Yana Stepanishyna, Martina Manni, Monica Civallero, Nazar Shokun, Tetiana Skrypets, Alevtyna Burtna, Natalia Shapovalenko, Iryna Tytorenko, Olena Aleksyk, Yan Pastushenko, Hanna Gubareva, Kateryna Moiseienko, Tetyana Kadnikova, Timur Rudyuk, Kateryna Filonenko, Arina Martynchyk, Olga Novosad, Giulia R. Galli, Irina Kryachok, Massimo Federico
SummaryWe report the outcome of 563 cases of newly diagnosed lymphoma registered in 2019–2021, including 176 cases (31.2%) of Hodgkin lymphoma (HL), 130 (23.1%) of diffuse large B‐cell lymphoma (DLBCL), 28 (5%) of follicular lymphoma (FL), 16 (2.9%) of mantle cell lymphoma (MCL) and 20 (3.5%) of peripheral T‐cell lymphoma (PTCL). After a median follow‐up of 30.1 months (95% CI: 28.8–31.3), the 3‐year
-
Diagnosis and management of smouldering myeloma: A British Society for Haematology Good Practice Paper Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-23 Daniel Hughes, Kwee Yong, Karthik Ramasamy, Simon Stern, Eileen Boyle, John Ashcroft, Faisal Basheer, Neil Rabin, Guy Pratt
-
The role of maintenance therapy following autologous stem cell transplantation in newly diagnosed multiple myeloma: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-23 Angela Hwang, Patrick Hayden, Charlotte Pawlyn, Donal McLornan, Laurent Garderet
SummaryRecent treatment advancements in multiple myeloma have led to significant improvements in patient outcomes. Maintenance therapy following autologous haematopoietic stem cell transplantation (AHCT) is now standard of care and has been demonstrated to prolong and deepen treatment responses. Currently, lenalidomide remains the single agent that has been approved for maintenance post‐AHCT in Europe
-
T/myeloid mixed phenotype acute leukaemia harbouring TLX3::BCL11B with TLX3 activation Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-22 Giovanni A. Botten, Yuannyu Zhang, Franklin Fuda, Prasad Koduru, Olga K. Weinberg, Tamra L. Slone, Ruifang Zheng, Kathryn E. Dickerson, Jeffrey R. Gagan, Weina Chen
SummaryT/myeloid mixed phenotype acute leukaemia (MPAL) is a rare aggressive acute leukaemia with poorly understood pathogenesis. Herein, we report two cases of T/myeloid MPAL harbouring BCL11B‐associated structural variants that activate TLX3 (TLX3::BCL11B‐TLX3‐activation) by genome sequencing and transcriptomic analyses. Both patients were young males with extramedullary involvement. Cooperative
-
The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-16 Helena Brillembourg, Núria Martínez-Cibrián, Mireia Bachiller, Leticia Alserawan, Valentín Ortiz-Maldonado, Sònia Guedan, Julio Delgado
-
Efficacy and safety of avatrombopag in Chinese children with persistent and chronic primary immune thrombocytopenia: A multicentre observational retrospective study in China Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-16 Zhifa Wang, Aijun Zhang, Zhongjin Xu, Nan Wang, Jialu Zhang, Jinxi Meng, Shuyue Dong, Jingyao Ma, Yu Hu, Juntao Ouyang, Zhenping Chen, Qi An, Xiaoling Cheng, Runhui Wu
Avatrombopag (AVA) is a novel thrombopoietin receptor agonist (TPO-RA) that has been recently approved as a second-line therapy for immune thrombocytopenia (ITP) in adults; however, its safety and efficacy data in children are lacking. Here, we demonstrated the efficacy and safety of AVA as second-line therapy in children with ITP. A multicentre, retrospective, observational study was conducted in
-
HLA peptide‐binding pocket diversity modulates immunological complications after cord blood transplant in acute leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-21 Wahid Boukouaci, Monica M. Rivera‐Franco, Fernanda Volt, Mohamed Lajnef, Ching‐Lien Wu, Hanadi Rafii, Barbara Cappelli, Graziana Maria Scigliuolo, Chantal Kenzey, Annalisa Ruggeri, Vanderson Rocha, Eliane Gluckman, Ryad Tamouza
SummaryPocket motifs and their amino acid positions of HLA molecules are known to govern antigen presentation to effector cells. Our objective was to analyse their influence on the risk of graft‐versus‐host disease (GVHD) and relapse after umbilical cord blood transplant (UCBT). The transplant characteristics of 849 patients with acute leukaemia were obtained from the Eurocord/EBMT database. Higher
-
The Mozart effect in chronic myeloid leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-20 Jesper Stentoft
Clinical research has not been able to establish whether the differences between first‐ and second‐generation BCR‐ABL 1 kinase inhibitors are clinically relevant with regard to outcome. In the study by Alcazer et al., a relevant difference seems to emerge—paradoxically in the absence of the drugs—as demonstrated by differences in the relapse kinetics after cessation of therapy.Commentary on: Alcazer
-
Outcomes in patients with multiple myeloma receiving salvage treatment after BCMA‐specific CAR‐T therapy: A retrospective analysis of LEGEND‐2 Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-19 Rui Liu, Rui Yang, Xuezhu Xu, Wanhong Zhao, Fangxia Wang, Wanggang Zhang, Bo Lei, Ruoyu Yang, Yiwen Wang, Aili He, Jianli Wang
SummaryChimeric antigen receptor T‐cell (CAR‐T) therapy targeting B‐cell maturation antigen (BCMA) has shown profound efficacy and manageable toxicity in patients with relapsed/refractory multiple myeloma (RRMM). However, determining the best course of treatment for post‐CAR‐T therapy relapse remains a significant challenge. We conducted a retrospective analysis of patients from the phase I LEGEND‐2
-
Idiopathic multicentric Castleman disease (iMCD)-idiopathic plasmacytic lymphadenopathy: A distinct subtype of iMCD-not otherwise specified with different clinical features and better survival Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-15 Yu-han Gao, Yan-ting Liu, Miao-yan Zhang, Si-yuan Li, David C. Fajgenbaum, Lu Zhang, Jian Li
-
Thromboembolic events, major bleeding and mortality in essential thrombocythaemia and polycythaemia vera—A matched nationwide population-based study Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-13 Anneli Enblom-Larsson, Henrik Renlund, Björn Andréasson, Henrik Holmberg, Maria Liljeholm, Anders Själander
Thromboembolic events and bleeding are known complications in essential thrombocythaemia (ET) and polycythaemia vera (PV). Using multiple Swedish health care registers, we assessed the rate of arterial and venous events, major bleeding, all-cause stroke and all-cause mortality in ET and PV compared to matched controls. For each patient with ET (n = 3141) and PV (n = 2604), five matched controls were
-
Cardiac effects of deferasirox in transfusion-dependent patients with myelodysplastic syndromes: TELESTO study Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-11 Matteo Sarocchi, Junmin Li, Xiao Li, Depei Wu, Efreen Montaño Figueroa, Maria Guadalupe Rodriguez, Ming Hou, Carlo Finelli, Hong-Xia Shi, Zhijian Xiao, Esther Natalie Oliva, Liana Gercheva Kyuchukova, Mark Drummond, Argiris Symeonidis, Eric J. Velazquez, Giulia Rivoli, Miguel Izquierdo, Yogita Kolekar, Paolo Spallarossa, Emanuele Angelucci
-
Symptom clusters and their impact on quality of life in multiple myeloma survivors: Secondary analysis of BMT CTN 0702 trial Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-13 Ruta Brazauskas, Kathryn Flynn, Amrita Krishnan, Heather Landau, Sergio Giralt, Marcelo C. Pasquini, Edward A. Stadtmauer, Anita D'Souza
Autologous haematopoietic cell transplantation (autoHCT) and continuous post-transplant maintenance therapy are the standard of care in transplant-eligible multiple myeloma (MM) patients. We sought to describe symptom burden and identify symptom clusters occurring in MM patients after autoHCT using data from the BMT CTN 0702 randomized controlled trial comparing the outcomes of three treatment interventions
-
The heart of VIALE-A: Cardiac complications of hypomethylating agents and venetoclax in acute myeloid leukaemia Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-09 Shyam A. Patel
As we commemorate 50 years since the introduction of classical 7 + 3 induction chemotherapy for acute myeloid leukaemia (AML), we also embark upon new territory with the advent of novel targeted therapeutics, including BH3 mimetics. To date, we do not have much large-scale longitudinal data regarding the toxicities of such novel therapies. Johnson et al. perform a comprehensive analysis of cardiac
-
Corrigendum to ‘FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia’ Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-08
Peschke JC, Bergmann R, Mehnert M, Gonzalez Soto KE, Loureiro LR, Mitwasi N, Kegler A, Altmann H, Wobus M, Máthé D, Szigeti K, Feldmann A, Bornhäuser M, Bachmann M, Fasslrinner F, Arndt C. FLT3-directed UniCAR T-cell therapy of acute myeloid leukaemia. Br J Haematol. 2023;202(6):1137–1150. The author list was incomplete. Christin Neuber was inadvertently omitted from the list of authors. She analysed
-
Patient preferences in the treatment of stage III/IV classic Hodgkin lymphoma: Results from the CONNECT cross-sectional survey Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-07 Darcy R. Flora, Susan K. Parsons, Nicholas Liu, Kristina S. Yu, Katherine Holmes, Carlos Flores, Michelle A. Fanale, Andy Surinach, Rachel Byrd, Andrew M. Evens
-
Clonal haematopoiesis: A common progenitor for cytotoxic peripheral T-cell lymphoma and angioimmunoblastic T-cell lymphoma Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-07 Antonio Vogelsberg, Lennart Harland, Vanessa Borgmann, Franziska Otto, Jan F. Weller, Dominik Nann, Leticia Quintanilla-Martinez, Falko Fend
Recent studies have shown that follicular helper T-cell lymphoma of angioimmunoblastic type (AITL), the most common nodal peripheral T-cell lymphoma (PTCL), frequently arises in a background of clonal haematopoiesis (CH), a preneoplastic condition affecting up to 40% of elderly individuals. Data on a potential CH association are limited for other PTCL. We report a unique patient who sequentially developed
-
BMP6 and VDR gene polymorphisms are associated with osteonecrosis in a sickle cell anaemia cohort Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-07 Gabriela S. Arcanjo, Mariana B. Souza, Igor F. Domingos, Diego A. Pereira-Martins, Diego A. Falcão, Jessica V. Batista, Betania L. Hatzlhofer, Madi V. Diniz, Alexsandro P. Silva, Werbson L. Guaraná, Manuela F. Hazin, Aderson S. Araujo, Anderson F. Cunha, Sara O. Saad, Fernando F. Costa, Antonio R. Lucena-Araujo, Marcos André C. Bezerra
-
Thrombotic and bleeding complications in patients with AL amyloidosis Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-06 Despina Fotiou, Foteini Theodorakakou, Sotiria Spiliopoulou, Maria Gavriatopoulou, Magdalini Migkou, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Panagiotis Malandrakis, Ioanna Dialoupi, Maria Roussou, Ioannis Ntanasis-Stathopoulos, Evangelos Terpos, Meletios A. Dimopoulos, Efstathios Kastritis
-
The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim Br. J. Haematol. (IF 6.5) Pub Date : 2024-02-06 Hanny Al-Samkari, Alexandra Schifferli, Tomas J. Gonzalez-Lopez
Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients.